Rates of Bleeding and Discontinuation of Direct Oral Anticoagulants in Patients With Decompensated Cirrhosis

被引:28
|
作者
Mort, Joseph F. [1 ]
Davis, Jessica P. E. [2 ]
Mahoro, Giselle [3 ]
Stotts, Matthew J. [2 ]
Intagliata, Nicolas M. [2 ]
Northup, Patrick G. [2 ]
机构
[1] Univ Virginia, Charlottesville, VA USA
[2] Univ Virginia, Sch Med, Ctr Coagulat Liver Dis, Div Gastroenterol & Hepatol,Dept Med, Charlottesville, VA 22908 USA
[3] Univ Virginia, Dept Med, Charlottesville, VA USA
关键词
INR; Real-World; Blood Clot; Drug; PORTAL-VEIN THROMBOSIS; ATRIAL-FIBRILLATION; COAGULOPATHY; DEFINITION; EFFICACY; DISEASE; SAFETY; RISK;
D O I
10.1016/j.cgh.2020.08.007
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Studies of the effects of direct oral anticoagulants (DOACs) in patients with cirrhosis have been limited by their small sample size, inclusion of patients with well-compensated cirrhosis, short follow-up times, inadequate validation of cirrhosis diagnoses, and non-standard definitions of bleeding. We aimed to systematically determine the characteristics, indications, and outcomes of patients with cirrhosis of all severity classes who received DOACs. METHODS: We performed a retrospective study of 138 patients with confirmed cirrhosis (93 with Child-Turcotte-Pugh scores of B or C) at a single center who started DOAC therapy (58,984 person-days; median, 181 days per patient) from September 2011 through April 2019. We collected data on clinical characteristics, indications for DOAC use, and outcomes. Standardized and validated definitions for bleeding complications were used. RESULTS: Twenty-nine patients (21%) stopped therapy due to a diagnosis of or perceived bleeding. The most common bleeding events were non-variceal upper and lower intestinal bleeding. No pretreatment laboratory parameters were associated with bleeding while patients received treatment, including platelet count (P = .50), international normalized ratio (P = .34), creatinine (P = .27), and model for end-stage liver disease score (P = .22). Frequency of bleeding events related to DOAC did not differ significantly among patients of different Child-Turcotte-Pugh classes (P = .81), DOAC indications (P = .60), or DOAC dosages (P = .10). Higher proportions of patients with hepatocellular carcinoma (P = .01) had major bleeding while receiving. CONCLUSIONS: Patients with decompensated cirrhosis have significant bleeding and rates of discontinuation of DOACs when they take them long term. Pretreatment laboratory parameters, DOAC dose, and Child-Turcotte-Pugh class were not associated with bleeding; hepatocellular carcinoma was associated with major bleeding.
引用
收藏
页码:1436 / 1442
页数:7
相关论文
共 50 条
  • [1] Direct acting oral anticoagulant use in cirrhosis patients: realworld bleeding and discontinuation rates
    Mort, Joseph
    Davis, Jessica
    Mahoro, Giselle
    Stotts, Matthew
    Intagliata, Nicolas
    Northup, Patrick
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S752 - S752
  • [2] Direct oral anticoagulants have similar rates of bleeding compared to traditional anticoagulants in compensated cirrhosis patients.
    Intagliata, Nicolas
    Henry, Zachary
    Maitland, Hillary
    Shah, Neeral L.
    Argo, Curtis K.
    Northup, Patrick
    Caldwell, Stephen H.
    [J]. HEPATOLOGY, 2015, 62 : 588A - 589A
  • [3] Direct Oral Anticoagulants Versus Preprohormone in Patients With Cirrhosis and the Risk of Gastrointestinal Bleeding
    Kostev, Karel
    Loosen, Sven
    Roderburg, Christoph
    Tanislav, Christian
    [J]. ANNALS OF PHARMACOTHERAPY, 2022, 56 (08) : 967 - 967
  • [4] RISK OF BLEEDING WITH ORAL ANTICOAGULANTS IN PATIENTS WITH LIVER CIRRHOSIS
    Aquite, Oriana Munevar
    Hayes, Michael
    Beyene, Kebede
    Chan, Amy
    Schauer, Cameron
    Wei, Henry
    Gong, Jay
    [J]. HEPATOLOGY, 2021, 74 : 1259A - 1260A
  • [5] Risk of bleeding with oral anticoagulants in patients with liver cirrhosis
    Gong, J.
    Hayes, M.
    Chan, A.
    Beyene, K.
    Wei, H.
    Schauer, C.
    Gong, J.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 38 - 38
  • [6] Bleeding management in patients with direct oral anticoagulants
    Heubner, Lars
    Vicent, Oliver
    Beyer-Westendorf, Jan
    Spieth, Peter M.
    [J]. MINERVA ANESTESIOLOGICA, 2023, 89 (7-8) : 707 - 715
  • [7] Predictors of Intracranial and Gastrointestinal Bleeding in Cirrhosis With Use of Direct Oral Anticoagulants
    Shah, Aun R.
    Hamid, Osama
    Butt, Muhammad U.
    Davila, Josue
    Walsh, Erin
    Kamionkowski, Sara
    Ghoneim, Sara
    Ali, Rubab
    Asaad, Imad
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S499 - S500
  • [8] Direct Oral Anticoagulants in Cirrhosis
    Nicolas M. Intagliata
    Hillary Maitland
    Stephen H. Caldwell
    [J]. Current Treatment Options in Gastroenterology, 2016, 14 (2) : 247 - 256
  • [9] Evaluation of the Use of Direct Oral Anticoagulants in Patients With Cirrhosis
    Dadlani, Apaar
    Kays, Lindsey
    Wade, Regan
    Bandikatla, Sudeepthi
    Barve, Ashutosh
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S1398 - S1398
  • [10] DIRECT ORAL ANTICOAGULANTS AS ALTERNATIVE TREATMENT FOR PVT IN PATIENT WITH DECOMPENSATED CIRRHOSIS: A NATIONWIDE ANALYSIS
    Chumbe, Julton Tomanguillo
    Annie, Frank
    Chittazhattu, Joel R.
    Ayoub, Mark
    Kemper, Suzanne
    Ullah, Hamid
    Iqbal, Sara
    Daglilar, Ebubekir
    Anwar, Nadeem
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S1351 - S1351